Atelosteogenesis type II is a rare genetic condition that affects how bones form before birth. It leads to very short limbs, joint differences, and underdeveloped lungs that cause severe breathing problems at delivery. Features are present in pregnancy and at birth, and the condition is lifelong. Most babies with atelosteogenesis type II have life‑threatening breathing difficulties, and many do not survive the newborn period. Care focuses on intensive breathing support, careful orthopedic management, and family-centered care, and genetic counseling may help parents understand future risks.
Overview
Atelosteogenesis type iiSymptoms
Early signs of atelosteogenesis type II appear at birth: very short limbs, underdeveloped bones, and multiple joint dislocations. A small, narrow chest can cause breathing difficulties. Some babies also have clubfeet or cleft palate, and distinctive facial features.
Outlook and prognosis
Many living with atelosteogenesis type II face serious breathing and mobility challenges from birth, and the condition is often life‑limiting in the newborn period. Care focuses on breathing support, comfort, and family-centered decisions. Survivors need specialized orthopedic and respiratory care.
Causes and risk factors
Atelosteogenesis type II results from harmful SLC26A2 gene variants and follows autosomal recessive inheritance. Risk rises when both parents are carriers, especially with consanguinity or a prior affected child. Environment or lifestyle are not causes.
Genetic influences
Genetics play a central role in Atelosteogenesis type II. It is caused by changes in the SLC26A2 gene, typically inherited in an autosomal recessive pattern. Carrier parents have a 25% chance per pregnancy to have an affected child.
Diagnosis
Doctors suspect Atelosteogenesis type II based on prenatal or newborn skeletal features and X-rays. Genetic tests of the FLNB gene confirm the diagnosis. When needed, ultrasound, CT, and expert radiology support the genetic diagnosis of Atelosteogenesis type II.
Treatment and drugs
Treatment focuses on breathing support at birth, careful airway and feeding management, and monitoring in intensive care. Specialists guide joint positioning, gentle casting or surgery for limb alignment, and tailored pain control. Families also receive genetic counseling and palliative care options.
Symptoms
Babies with Atelosteogenesis type ii are born with very short arms and legs, multiple joint differences, and a small, narrow chest that can make breathing hard. Features vary from person to person and can change over time. Many families first hear about early features of Atelosteogenesis type ii during a pregnancy scan or right after birth, such as noticeable limb shortening or joints that sit out of place. These differences shape day-to-day care, from breathing support in the newborn period to help with feeding and comfortable positioning.
Arms and legs are much shorter than expected at birth. This limits reach and makes positioning and daily care more involved.
Hips, knees, elbows, or shoulders may be out of place at birth. This can restrict movement and may require splints or surgery.
In Atelosteogenesis type ii the chest is narrow and may not let the lungs expand fully. Breathing support is often needed right after birth and can be life-threatening in severe cases.
Feet may turn inward (clubfoot) and thumbs can be angled outward like a hitchhiker’s. These differences can affect grip and early weight-bearing.
How people usually first notice Atelosteogenesis type ii?
Most families first notice atelosteogenesis type II during pregnancy, when an ultrasound shows markedly short limbs, a small chest, and clubfeet, often prompting genetic testing to look for FLNB gene changes. If it isn’t flagged prenatally, the first signs of atelosteogenesis type II are usually obvious at birth: very short arms and legs, joint contractures, underdeveloped lungs due to a narrow chest, and facial differences such as a small lower jaw. Doctors typically recognize the pattern immediately and confirm the diagnosis with imaging and genetic testing, given that this severe skeletal condition is present from the start of life.
Types of Atelosteogenesis type ii
Atelosteogenesis type II is a rare genetic skeletal condition present from birth. Clinicians often describe them in these categories: while AO type II is a distinct diagnosis, it sits within a small family of related skeletal dysplasias caused by changes in the same gene, which can shape severity and day-to-day function. People may notice different sets of symptoms depending on their situation. Understanding the types of atelosteogenesis can help families anticipate care needs and how symptoms may differ across closely related diagnoses.
AO type II (classic)
This variant involves severe underdevelopment of many bones with joint dislocations, very short limbs, and underdeveloped chest. Breathing problems at birth are common because the ribs and chest are small. Facial features and finger/toe differences can also be present.
AO type I
This related variant shares many features with AO type II but tends to have different bone shapes and patterns of joint dislocation. Limb shortening is severe, and the chest is small, but details on x‑rays help distinguish it. Early symptoms of atelosteogenesis in this type overlap with type II, though skeletal patterns differ.
AO type III
This type is also part of the atelosteogenesis spectrum with severe limb shortening and multiple joint dislocations. Compared with type II, some bone segments may be more formed, but the overall severity remains high. Breathing and feeding support at birth is often needed.
Diastrophic dysplasia
This is a related skeletal dysplasia from changes in the same gene and can be less severe than AO types. People with this variant often have short stature, clubfoot, and joint contractures, with a more developed chest than in AO II. Newborn breathing support may be needed but survival into childhood and adulthood is more common.
Achondrogenesis type IB
This condition lies at the most severe end of the same genetic spectrum and is often lethal in the newborn period. Bones are extremely underdeveloped, with very short limbs and a very small chest. Features can overlap with AO II, but the overall skeletal development is more limited.
What genetics can tell you about symptoms
Certain FLNB gene changes disrupt how cartilage turns into bone, leading to very short limbs, joint dislocations, a small chest, and distinct facial features; these are features doctors see, while babies may show breathing difficulty and poor feeding as symptoms. Specific variants can weaken the rib and airway structures more severely, linking to early respiratory distress and higher risk of life-threatening complications at birth.
Causes and risk factors
Atelosteogenesis type ii is caused by a harmful change in the FLNB gene.
Some risks are written in our DNA, passed down through families.
Most cases happen as a new gene change, so there may be no family history.
If a parent carries the change, the chance for each pregnancy is about 50%.
There are no known lifestyle or environmental risks, so risk factors for Atelosteogenesis type ii mainly relate to family history or a rare hidden change in a parent’s eggs or sperm.
Environmental and biological risk factors
If you’re looking for what in your body or surroundings might raise the chance of this diagnosis, the picture is limited. For atelosteogenesis type ii, environmental risk factors haven’t been clearly shown. Doctors often group risks into internal (biological) and external (environmental). Based on current evidence, no specific external exposures or parent-age patterns have been confirmed to increase the likelihood.
No consistent link has been found between older maternal or paternal age and atelosteogenesis type ii. Current data do not show a clear age-related pattern in occurrence.
Common pregnancy infections have not been shown to increase the likelihood of this condition. Routine vaccination and prenatal care remain important for overall fetal health.
Conditions such as diabetes, thyroid disease, or autoimmune disorders have no established association with this condition. Managing these conditions still supports general pregnancy health.
No specific medicines have been confirmed to raise the risk of atelosteogenesis type ii. Always review any prescription or over-the-counter drugs with your prenatal team.
Genetic risk factors
Atelosteogenesis type II most often results from changes in a single gene called SLC26A2 that affect how cartilage and bone form before birth. Some risk factors are inherited through our genes. The genetic risk factors for atelosteogenesis type II mainly involve two carrier parents passing on non-working copies of this gene. Family history may be absent because carriers typically have no symptoms.
SLC26A2 variants: Changes in this gene disrupt a process cartilage cells need to grow properly. Two non-working copies typically lead to atelosteogenesis type II. Different changes in the same gene can cause a spectrum of related skeletal conditions.
Autosomal recessive: A child must inherit two altered copies—one from each parent—to be affected. When both parents are carriers, each pregnancy has a 25% (1 in 4) chance of atelosteogenesis type II.
Carrier parents: Carriers have one altered and one working copy and typically have no symptoms. Two carriers together have a higher chance of having an affected child, even without any family history.
Variant severity: Combinations of two severe, loss-of-function changes are more likely to cause atelosteogenesis type II. Pairings that leave some gene activity can lead to milder SLC26A2 conditions.
Parental relatedness: Parents who share recent ancestry are more likely to carry the same rare variant. This increases the chance a child will inherit two altered copies.
Founder variants: Some populations have higher carrier rates of specific SLC26A2 changes due to founder effects. Risk may be higher when both parents come from the same high-carrier community.
De novo changes: New mutations in SLC26A2 are uncommon causes because two altered copies are usually inherited. Most families with atelosteogenesis type II involve two healthy carrier parents.
Recurrence risk: After one affected pregnancy, the chance of the same couple having another affected child is 25% (1 in 4) each time. Unaffected siblings have a 2 in 3 chance of being carriers.
Lifestyle risk factors
Lifestyle choices do not cause Atelosteogenesis type ii, but they can influence comfort, symptom control, and complications over time. Gentle, tailored routines around movement, feeding, sleep, and daily care can support breathing and joint stability. Understanding how lifestyle affects Atelosteogenesis type ii helps families prioritize strategies that make day-to-day life safer and more manageable. Work closely with the care team to individualize these approaches.
Therapist-guided range-of-motion helps maintain flexibility and may reduce joint contractures and pain. Forceful stretching or unsupervised manipulation can worsen dislocations in unstable joints.
Neutral alignment of neck, spine, and limbs helps protect fragile joints and keeps the airway more open. Avoid chin-to-chest or prone positions that can compress a small chest and impede breathing.
Short, low-exertion activities spaced with rest reduce fatigue and breathlessness in the setting of a narrow chest. Overexertion can aggravate respiratory compromise and increase recovery time.
Calorie-dense, nutrient-rich feeds support growth, healing, and respiratory muscle energy needs. Poor intake or prolonged, tiring feeds can worsen fatigue and growth failure.
Risk prevention
Atelosteogenesis type ii is a rare, usually severe genetic bone condition present from birth, so there’s no way to prevent the condition itself. Prevention efforts focus on family planning options, early detection in pregnancy, and preparing for specialized care to reduce complications for the baby and the family. Some prevention is universal, others are tailored to people with specific risks. Decisions are deeply personal, and your medical team can help you understand options and timing.
Meet with a genetics professional to review how atelosteogenesis type ii happens and your family’s chance of recurrence. They can outline testing options before or during pregnancy and help with planning.
If a previous pregnancy or child was affected, targeted genetic testing can check whether one parent carries a known FLNB change. This helps estimate future risk and guides reproductive choices.
With IVF, embryos can be tested for the known family variant before transfer. This option may reduce the chance of another affected pregnancy, though it does not guarantee pregnancy success.
Detailed ultrasound can spot early signs of severe limb and chest differences; some call these early symptoms of atelosteogenesis type ii, but they are ultrasound features rather than felt symptoms. Diagnostic testing by CVS or amniocentesis can confirm the specific genetic change.
Transmission
Atelosteogenesis type ii is a genetic condition, not an infection, so it cannot be caught or spread through contact. It follows autosomal recessive inheritance: if both parents carry one changed copy of the gene, each pregnancy has a 25% (1 in 4) chance of a child with Atelosteogenesis type ii and a 50% (1 in 2) chance of a carrier; carriers typically have no symptoms.
The chance is the same for boys and girls and repeats with each pregnancy, and most cases occur when both parents are carriers; new genetic changes are uncommon. If you have questions about how Atelosteogenesis type ii is inherited, a genetics team can explain risks for your family and discuss carrier or prenatal testing.
When to test your genes
Consider genetic testing when a newborn shows features consistent with severe skeletal differences, when prenatal imaging suggests shortened limbs, or if there’s a family history of lethal skeletal dysplasias. Confirmatory testing of the FLNB gene can guide diagnosis, delivery planning, and neonatal care. Parents considering future pregnancies may also pursue carrier testing and prenatal options.
Diagnosis
Diagnosis usually happens during pregnancy or shortly after birth, based on distinctive bone, joint, and chest features. Early and accurate diagnosis can help you plan ahead with confidence. Doctors confirm Atelosteogenesis type ii with imaging and genetic tests that look for changes in a specific gene.
Sonographers look for very short arms and legs, a small chest, and joint positions that don’t look typical. These patterns can suggest a severe skeletal difference and prompt closer follow-up. For some, routine check-ups reveal the first clues.
MRI during pregnancy can help measure chest size and give a clearer view of the lungs. This can inform discussions about breathing support and delivery planning.
Right after birth, clinicians assess limb length, joint movement, hand and foot shape, and the size of the ribcage. The overall pattern of features can strongly point to Atelosteogenesis type ii.
A full set of X-rays checks bone shape, length, and how well the bones have hardened. Certain combinations of findings help distinguish this condition from other skeletal dysplasias.
Stages of Atelosteogenesis type ii
Atelosteogenesis type ii does not have defined progression stages. It develops before birth and is usually recognized on prenatal imaging or at delivery, so it doesn’t follow a gradual course over time. Ultrasound before birth and X-rays after delivery are the main tests; Genetic testing may be offered to clarify certain risks. When early symptoms of Atelosteogenesis type ii are suspected on a routine scan, referral to a specialist team helps confirm the diagnosis and discuss care.
Outlook and prognosis
Looking at the long-term picture can be helpful. For many people with Atelosteogenesis type II, the first hours to days after birth are the most critical. Severe underdevelopment of the chest and lungs, along with airway and rib differences, often leads to life‑threatening breathing problems. Because of this, newborn survival is limited without intensive respiratory support; even with advanced care, early mortality is unfortunately common. When breathing can be stabilized, care shifts to managing joint dislocations, very short limbs, and spine differences that affect comfort, movement, and growth.
Prognosis refers to how a condition tends to change or stabilize over time. In Atelosteogenesis type II, the outlook is strongly influenced by how well the lungs and airway can function and by the extent of skeletal changes seen on imaging. Early symptoms of Atelosteogenesis type II may include respiratory distress, difficulty feeding, and limited movement due to joint instability; longer term, there can be recurring chest infections, curvature of the spine, and mobility challenges. Some centers report that a small number of children who survive the newborn period can live into childhood with ongoing, specialized care, though this remains rare. Quality of life for survivors depends on access to coordinated care in intensive care, orthopedics, pulmonology, and nutrition.
Families often want to know what role they can play.. If you’re planning a pregnancy or have a known family history, prenatal imaging and, in some cases, genetic testing can help anticipate needs at delivery. Not everyone with the same gene change will have the same outlook. Talk with your doctor about what your personal outlook might look like.
Long-term effects
Atelosteogenesis type ii is a severe genetic skeletal condition with a very high risk of death before or shortly after birth. Early signs of Atelosteogenesis type ii are often visible on prenatal ultrasound, and the long-term picture is typically shaped by breathing problems from a very small chest. Among rare survivors, health challenges tend to be ongoing and mainly involve the lungs, spine, and mobility. Long-term effects vary widely, but they usually reflect how much the chest and bones were affected early on.
Most pregnancies with Atelosteogenesis type ii end in stillbirth or infants die soon after birth because the chest is too small for effective breathing. When survival occurs, it is exceptional and medical needs are intensive.
In Atelosteogenesis type ii, underdeveloped ribs and a very small chest limit lung growth. This often leads to chronic breathing problems and low oxygen levels over time.
A small, rigid chest restricts air movement. Over time this can cause recurrent respiratory infections and limited activity tolerance.
Marked limb shortening and joint stiffness limit movement and motor development. Many living with Atelosteogenesis type ii who survive have significant physical disability.
How is it to live with Atelosteogenesis type ii?
Living with atelosteogenesis type II often means navigating life in a body that is small and structurally fragile, with significant differences in limb length and joint shape that affect movement, comfort, and independence. Daily life usually involves frequent medical visits, adaptations for mobility and positioning, help with personal care, and equipment that makes breathing, feeding, and safe transport easier. Families and caregivers become partners in care, learning how to support comfort, prevent complications, and celebrate progress, while also managing the emotional and logistical weight of complex needs. Many find that planning ahead, clear communication with the care team, and a supportive community make everyday moments more manageable and more meaningful.
Treatment and drugs
Treatment for atelosteogenesis type II focuses on supportive care, easing symptoms, and preventing complications, since there’s no medicine that can reverse the underlying bone development changes. Care often starts at birth in a neonatal intensive care unit, with careful breathing support, management of chest and airway differences, and monitoring for infections. Orthopedic care may include gentle casting or splints for joint positioning, and later, selective surgeries to improve stability or comfort; doctors sometimes recommend a combination of lifestyle changes and drugs, such as pain relievers and medicines that support lung health. Physical and occupational therapy can help with positioning, safe handling, and comfort, while nutrition support aims to maintain growth and strength. Finding the right therapy can take some time, so care is usually coordinated by a team that may include neonatology, pulmonology, orthopedics, genetics, and palliative care to align treatment with family goals and quality of life.
Non-drug treatment
Care often focuses on comfort, breathing, feeding, and safe positioning from the first hours of life. Supportive therapies can steady day-to-day care while medical teams monitor for complications. Because Atelosteogenesis type ii is a severe skeletal condition, most care is supportive and tailored to each baby’s needs. Plans may shift over time, with goals centered on safety and quality of life for the child and family.
Early symptoms of Atelosteogenesis type ii are often seen on prenatal scans, so planning ahead helps set up the right care. Coordinating a delivery at a hospital with newborn intensive care can make immediate support smoother.
Having a neonatal team ready can help with breathing, airway support, and safe handling at birth. Discussing delivery method and equipment needs in advance can reduce urgent decisions in the delivery room.
Babies with Atelosteogenesis type ii may need oxygen, gentle breathing machines, or careful airway positioning. The goal is to ease work of breathing and protect fragile ribs and lungs.
Soft supports and careful positioning help protect the neck, spine, and joints. Nurses and therapists can teach families comfortable holds and transfers for daily care.
Your genes may have an impact on how drugs work for you
Even when the diagnosis is the same, people with atelosteogenesis type II can process pain medicines, antibiotics, and anesthesia differently because drug‑handling genes vary. Pharmacogenetic testing and careful dose-by-dose monitoring help clinicians choose safer, more effective medications.
Pharmacological treatments
There’s no medicine that can change the bone development problems in Atelosteogenesis type ii, so care focuses on comfort and complications. Drugs that target symptoms directly are called symptomatic treatments. Because early symptoms of Atelosteogenesis type ii often involve breathing difficulties, medicines may be used alongside breathing support in the neonatal unit. Choices depend on each baby’s needs and are adjusted often as things change.
Acetaminophen (paracetamol) is used first for discomfort and fever. Morphine may be added for procedures or severe pain, with close monitoring for slowed breathing and constipation.
Surfactant (such as poractant alfa or beractant) can be given in the delivery room or NICU if there is respiratory distress syndrome. Caffeine citrate may be used for apnea spells in premature or fragile newborns.
If infection is suspected, doctors often start ampicillin plus gentamicin while waiting for culture results. Antibiotics are then narrowed or changed based on the specific bacteria and your baby’s response.
Furosemide may help if fluid buildup strains the heart or lungs. Dosing may be increased or lowered gradually to balance breathing comfort with risks like electrolyte shifts or hearing effects.
Genetic influences
Atelosteogenesis type ii stems from inherited changes in a gene that helps cartilage form and grow. In most families, the gene involved is SLC26A2, and the condition is autosomal recessive—children are affected when they inherit one nonworking copy from each parent. A “carrier” means you hold the gene change but may not show symptoms. If both parents are carriers, each pregnancy has a 25% chance of Atelosteogenesis type ii, a 50% chance the child will be a carrier, and a 25% chance the child will inherit neither change. Different SLC26A2 changes can leave more or less function, which is why the same gene is linked to a spectrum ranging from very severe to milder skeletal differences. Genetic testing can often pinpoint the specific change, confirm the diagnosis, and support carrier testing or prenatal options. Understanding the genetic causes of Atelosteogenesis type ii can help families discuss risks, planning, and support with their care team.
Is Atelosteogenesis type ii genetic?
Genetics play a central role in Atelosteogenesis type II. It is caused by changes in the SLC26A2 gene, typically inherited in an autosomal recessive pattern. Carrier parents have a 25% chance per pregnancy to have an affected child.
Pharmacogenetics—how genetics influence drug effects
For Atelosteogenesis type ii, the gene change that drives the bone and cartilage features does not, by itself, tell doctors which medicines will work best. There isn’t a targeted drug for this condition yet, so care focuses on breathing support, preventing infections, pain control, and careful planning for surgery and anesthesia; any pharmacogenetic decisions center on general drug‑response genes rather than the condition’s gene. Alongside medical history and current medicines, genetic testing can sometimes identify how your body handles certain pain relievers or anti‑nausea drugs, which may help avoid side effects. Differences in common liver enzymes can change how codeine or tramadol are processed, so these medicines are often avoided in children and teens; if they’re considered later in life, a pharmacogenetic result may guide safer dosing or alternatives. For anesthesia, teams tailor medicines to airway and chest size and will ask about any family history of anesthesia reactions, which can be genetic even though they’re not part of Atelosteogenesis type ii itself. While not routine, general pharmacogenetic testing for medication response in people with Atelosteogenesis type ii may be considered when multiple medicines are needed, aiming to reduce side effects and drug interactions.
Interactions with other conditions
Respiratory infections can have an outsized impact because the small chest and airway changes in atelosteogenesis type ii reduce breathing reserves; even a routine cold may lead to serious breathing difficulty. Certain diseases may “overlap,” meaning features of atelosteogenesis type ii can resemble other skeletal conditions in the same gene family, such as diastrophic dysplasia or achondrogenesis type 1B, and this overlap matters for diagnosis and family planning. Early symptoms of atelosteogenesis type ii are often first seen on prenatal ultrasound and can look similar to thanatophoric dysplasia or severe forms of osteogenesis imperfecta, so teams may involve genetics and radiology to sort out which condition is present. If a newborn survives the early period, joint dislocations and spine curvature can complicate care for lung and heart health, and treatments for one issue (like anesthesia or bracing) may need adjustment to avoid worsening another. The presence of another illness does not always mean outcomes will be worse, but prompt treatment of infections and coordinated care can reduce risks.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described newborns with very short limbs, a small chest, and joints that seemed fixed in place. Families and midwives recalled babies who struggled to breathe right after birth, while doctors noted that X-rays showed unusually shaped bones. These early stories captured the visible features, even when the underlying cause was still a mystery. Some records grouped different skeletal conditions together, which made it hard to tell them apart.
First described in the medical literature as a severe form of skeletal dysplasia, atelosteogenesis type II was initially recognized by its striking appearance on imaging: very short thigh and upper arm bones, curved lower legs, and changes in the spine and pelvis. Over time, descriptions became more precise as clinicians compared cases from different hospitals and countries. Pathology reports and prenatal ultrasound findings helped define a consistent pattern, separating atelosteogenesis type II from look-alike conditions that share short-limb features but follow a different course.
In recent decades, knowledge has built on a long tradition of observation. Advances in genetics connected these clinical signs with changes in a specific gene involved in cartilage and bone growth. That link explained why the skeleton forms differently and why the condition can be life-limiting, often due to lung underdevelopment in a very small chest. Genetic testing also clarified why some cases appeared suddenly in a family with no prior history: many changes arise for the first time in the egg or sperm rather than being inherited from a parent.
Despite evolving definitions, the core picture of atelosteogenesis type II has stayed steady: distinctive limb and chest findings seen before birth or at delivery, with X-ray features that guide diagnosis. What has changed is the ability to confirm the diagnosis with a genetic test, offer accurate counseling about recurrence risks, and plan supportive care tailored to each baby. Looking back helps explain why earlier reports seemed inconsistent; they were viewing a rare condition through limited tools. Today, a shared language across imaging and genetics ties those threads together and supports clearer communication with families facing atelosteogenesis type II.